Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

(A Development Stage Company) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, ---------------------------- 2009 2008 ------ ------ Operating expenses: Research and development(1) $2,326 $5,781 General and administrative(2) 2,189 2,487 ------ ------ Total operating expenses 4,515 8,268 ------ ------ Loss from operations (4,515) (8,268) Interest income 33 504 Interest expense (120) (243) Other income (expense), net -- 17 -------- -------- Net loss $(4,602) $(7,990) ======== ======== Basic and diluted net loss per share attributable to common stockholders $(0.26) $(0.46) ======== ======== Shares used to compute basic and diluted net loss per share attributable to common stockholders 17,568,600 17,468,395 ========== ========== Non-cash stock-based compensation expense included in operating expenses: (1) Research and development $259 $198
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015   Intrexon Corporation (NYSE: ... today the appointment of Olivier R. Jarry ... Mr. Jarry will lead the expansion of Intrexon,s programs ... for consumer markets.  Mr. Jarry ... in leading global life sciences and consumer health ...
(Date:6/2/2015)... 2015 GOJO, inventors of PURELL ® ... stewardship at the White House Forum.  GOJO was among ... and stakeholders at the White House Forum to announce ... emergence of antibiotic-resistant bacteria, detect resistant strains, preserve the ... of resistant infections. "A primary prevention approach ...
(Date:6/1/2015)... Chosen for his engaging style ... has been selected as keynote speaker for a ... will deliver his keynote: "Don't Stop Thinking About ... to the American Medical Association, Blue Cross Blue ... Forum on Wireless Healthcare, United Healthcare, IASIS Healthcare, ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
Breaking Biology Technology:Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... , BIRMINGHAM, Ala. , Jan. 19 ... when it comes to cholesterol. According to a new study, a ... — can be labeled "bad cholesterol." The landmark study Genetic ... published in the New England Journal Of Medicine provides ...
... , , NEW HAVEN, Conn. , ... today that it has appointed Dr. Richard J. Carroll ... Research. , Dr. Carroll brings to HistoRx over 20 years ... diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in ...
... CITY, China , Jan. 19 /PRNewswire-Asia-FirstCall/ -- ... fully,integrated and highly innovative biopharmaceutical company engaged in the,research and ... today announced financial results for the second quarter ended, November ... 2010 Highlights, -- Total revenue increased by ...
Cached Biology Technology:New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 3HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3Sinobiopharma Announces Second Quarter 2010 Financial Results 2Sinobiopharma Announces Second Quarter 2010 Financial Results 3Sinobiopharma Announces Second Quarter 2010 Financial Results 4
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... 18, 2009 Pharmaceuticals and personal care products (PPCPs) ... reach surface waters or groundwater when these materials ... the high flow conditions created by land application ... of solutes in soil macropores may be too ...
... radiation therapy treatment damages a patient,s healthy tissue as ... destroy, making the treatment especially invasive and often causing ... will enable a far more precise and accurate treatment ... the radiation beam. Real-time image-guided radiotherapy, combining radiation ...
... available in French . , Montreal, May ... known to humans, and its abuse has become widespread since ... we know rather little about its effects on the human ... latest article by Dr. Marco Leyton, of the Montreal Neurological ...
Cached Biology News:Simulating pharmaceutical and personal care product transport 2Cocaine: Perceived as a reward by the brain? 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: